List price of EPZM’s Tazverik is $186K per year ($15,500/month; $510/day), according to the company’s CC today. Of course, many patients with epithelioid sarcoma won’t survive a full year on treatment.
h/t @NedPagliarulo.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”